SGLT2 Inhibitors in Patients With Polycystic Ovarian Syndrome

• Status: Enrolling by invitation
• Trial end date: 2021-04-30
• Target enrollment: 0
• Participant gender: Female

Summary

Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to 15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other metabolic abnormalities. Metformin has been clarified as an option in patients with PCOS. However, the clinical responses to metformin are limited and different. Sodium glucose co-transporter 2 (SGLT2) inhibitors are novel drugs for the treatment of type 2 diabetes, with weight loss, reducing insulin resistance and cardiovascular benefits. Limited data is available on the efficacy of SGLT2 inhibitors in patients with PCOS.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai 10th People's Hospital
• Treatments: Canagliflozin; Metformin; Sodium-Glucose Transporter 2 Inhibitors

Criteria

Inclusion criteria:

• Fmale aged 18- 45;

• Meet Rotterdam criteria;

• Insulin Rsistance

Exclusion Criteria:

• Women who are pregnant or have a pregnancy plan within six months; ·Congenital adrenocortical hyperplasia;

• Hyperprolactinemia;

• Hyperthyroidism or hypothyroidism;

• Abnormal liver function (≥ 3 times of the upper limit of normal range);

• Abnormal renal function (GFR<60ml/min/1.73m2);

• Adrenal or ovarian tumors secreting androgens;

• Used contraceptives, metformin, GLP-1RA, pioglitazone and contraceptives in the last 3 month.